RxDoctor Payments Data

Daniel McDonald, MD

Family Medicine · Jasper, ALNPI 1225067051

Payments from drug & device makers

$8,182in general payments, 2019–2025

Across 150 payments — averaging $54.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • GSK$459
  • Novo Nordisk$440
  • Paratek Pharmaceuticals, Inc.$125
  • AstraZeneca$124
  • Currax Pharmaceuticals LLC$13

What the payments were for

  • Speaking & faculty fees$5,00061%
  • Food & beverage$3,17439%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)102$7,021
GSK38$459
Novo Nordisk6$440
Paratek Pharmaceuticals, Inc.1$125
AstraZeneca2$124
Currax Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,182 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$42,722
Medicare patients
197
Services billed
2,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$21,859
Cefdinir169$3,812
Albuterol Sulfate HfaAlbuterol Sulfate153$3,156
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$2,196
PaxlovidNirmatrelvir/Ritonavir15$1,429
ProgesteroneProgesterone, Micronized29$1,263
Ciprofloxacin Hcl74$765
Ondansetron OdtOndansetron86$700
Clindamycin Hcl39$408
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav28$372
Permethrin13$371
Prednisone234$348
Oseltamivir Phosphate11$332
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$314
Mupirocin32$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$459$21,85934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Jasper

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →